While the findings are observational and most participants in the study were older white men with diabetes, which could limit how broadly the results apply to other groups, experts not involved in the study said they provide a helpful big-picture view
Current NHS eligibility criteria for semaglutide 2.4 mg (Wegovy) for weight management, according to NICE TA875, include: Body Mass Index (BMI) 35 kg/m with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea) For people from certain high-risk ethnic groups (such as South Asian, Chinese, Black African, or African-Caribbean), lower BMI thresholds apply (typically reduced by 2.5 kg/m) Treatment must be prescribed within specialist weight management services only Treatment is limited to a maximum duration of 2 years Must be used as an adjunct to a reduced-calorie diet and increased physical activity Liraglutide 3 mg (Saxenda) availability varies significantly across NHS regions and is not routinely commissioned in many areas
0.72), Mobility (0.69
Food and Drug Administration 2024 2 Drucker DJ Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1 Cell Metabolism 27(4) 2018PMID: 29617641 PubMed 3 Bezin J, Gouverneur A, Penichon M, et al
Metabolic biomarkers tell the story that BMI misses entirely
We strictly adhere to research-use-only policies to maintain compliance with regulatory standards
